Perimeter Medical Imaging AI, Inc. (TSXV:PINK) (OTCQX:PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company is pleased to announce that its CEO, Adrian Mendes, will present a Company update regarding current commercial strategy and discuss upcoming milestones at the Planet MicroCap Showcase on Wednesday, October 22, 2025 at 12:00 p.m. Eastern Time. https://mma.prnewswire.com/media/2798724/Perimeter_Medical_Imaging_AI_Inc__Perimeter_Medical_Imaging_AI_t.jpg Hosted […]

ID.me and Flexpa today announced a partnership to make it easier and safer for patients to access and share their medical records – replacing outdated processes, reducing AI-driven fraud, and advancing the Centers for Medicare & Medicaid Services (CMS) vision of true interoperability. ID.me is the next-generation digital identity wallet trusted by more than 154

Paramount Skydance Corporation (Nasdaq: PSKY) announced today that it will report third quarter 2025 financial results onMonday, November 10, 2025. The company will conduct a conference call at1:30 p.m. (PT) / 4:30 p.m. (ET)following the release of its earnings materials. A live audio webcast will be available onParamount'sInvestors homepage atir.paramount.combeginning at1:30 p.m. (PT) / 4:30

Fleet electrification expected to reduce costs and deliver quieter, cleaner rides for students Hingham Public Schoolswill host a groundbreaking ceremony to celebrate construction of the district's first electric school bus project. The switch from three diesel school buses to three electric school buses is projected to save the district $10,000-$20,000 each year and deliver quieter,

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2–, high-risk early breast cancer Seven-year results from the Phase 3 monarchE trial also show Verzenio plus endocrine therapy demonstrated sustained benefits in invasive disease-free survival and distant relapse-free survival These data were simultaneously published

Topline resultsand additional data from the pivotal SynAIRgy and LunAIRo Phase 3 studies – the largest clinical program of an investigational medication for obstructive sleep apnea (OSA)- show that AD109 achieved significant reduction in apnea-hypopnea index (AHI) at 26 weeks, meeting primary endpoints in both trials, and consistently improved key secondary endpoints related to oxygenation,

BancFirst Corporation (NASDAQ GS:BANF) reported net income of $62.7 million, or $1.85 per diluted share, for the third quarter of 2025 compared to net income of $58.9 million, or $1.75 per diluted share, for the third quarter of 2024. The Company's net interest income for the three-months ended September 30, 2025 increased to $125.6 million

(NasdaqGM:NKLR), NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors, today filed a new investor presentation including updates to the timeline for the deployment of its first-of-a-kind (“FOAK”) SOLO(TM) micro-modular reactor solution and commercialization. The Company now expects FOAK

(NASDAQ:LAES), Geneva, Switzerland, Oct. 17, 2025 (GLOBE NEWSWIRE) — From Catalog ICs to Custom ICs and Security IP, a unified offering to shape the post-quantum era. SEALSQ Corp (NASDAQ: LAES), a global leader in semiconductors and Post-Quantum Cryptography (PQC) solutions, today announced its integrated strategy for IC'Alps, the French ASIC design house recently acquired by

(NASDAQ:AGIO), CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication